One of the kinases identified as a ‘druggable’ target is the checkpoint kinase, CHK1, and for this reason, CHK1 inhibitors (CHK1i) represent a potential new class of anti-cancer therapies, and are currently in clinical trials [1]. This evidence concerns the gene CHEK1 and cancer.